Key Details
Annual ROE
-257.91%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 16, 2023Recent annual earnings:
Mar 09, 2021Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
No data about analysts updates
Screeners with ALNA included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Allena Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Allena Pharmaceuticals?
- What is the ticker symbol for Allena Pharmaceuticals?
- Does Allena Pharmaceuticals pay dividends?
- What sector is Allena Pharmaceuticals in?
- What industry is Allena Pharmaceuticals in?
- What country is Allena Pharmaceuticals based in?
- When did Allena Pharmaceuticals go public?
- Is Allena Pharmaceuticals in the S&P 500?
- Is Allena Pharmaceuticals in the NASDAQ 100?
- Is Allena Pharmaceuticals in the Dow Jones?
- When was Allena Pharmaceuticals's last earnings report?
- When does Allena Pharmaceuticals report earnings?
What is the primary business of Allena Pharmaceuticals?
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.
What is the ticker symbol for Allena Pharmaceuticals?
The ticker symbol for Allena Pharmaceuticals is NASDAQ:ALNA
Does Allena Pharmaceuticals pay dividends?
No, Allena Pharmaceuticals does not pay dividends
What sector is Allena Pharmaceuticals in?
Allena Pharmaceuticals is in the Healthcare sector
What industry is Allena Pharmaceuticals in?
Allena Pharmaceuticals is in the Biotechnology industry
What country is Allena Pharmaceuticals based in?
Allena Pharmaceuticals is headquartered in United States
When did Allena Pharmaceuticals go public?
Allena Pharmaceuticals's initial public offering (IPO) was on 02 November 2017
Is Allena Pharmaceuticals in the S&P 500?
No, Allena Pharmaceuticals is not included in the S&P 500 index
Is Allena Pharmaceuticals in the NASDAQ 100?
No, Allena Pharmaceuticals is not included in the NASDAQ 100 index
Is Allena Pharmaceuticals in the Dow Jones?
No, Allena Pharmaceuticals is not included in the Dow Jones index
When was Allena Pharmaceuticals's last earnings report?
Allena Pharmaceuticals's most recent earnings report was on 16 May 2023
When does Allena Pharmaceuticals report earnings?
The date for Allena Pharmaceuticals's next earnings report has not been announced yet